The Effect of Verapamil on the Pharmacokinetics of Adriamycin

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1986 Jan 1

PMID 3026675

Citations 39

Authors

D J Kerr

J Graham

J Cummings

J G Morrison

G G Thompson

M J Brodie

S B Kaye

Affiliations

Soon will be listed here.

Abstract

The concurrent administration of adriamycin (intravenous) and verapamil (oral) is of considerable interest because of experimental data suggesting that resistance to adriamycin may be overcome by this means. The potential for a pharmacokinetic interaction between the two drugs has therefore been investigated in five patients with small cell lung cancer treated with combination chemotherapy comprising adriamycin, VP16, vincristine and cyclophosphamide. The data indicate that a significant interaction takes place. Adriamycin peak levels, terminal half-life and the volume of distribution at steady state are higher, whereas plasma drug clearance and the volume of the central compartment are lower with co-administration of verapamil. There was no evidence of enhanced drug toxicity in this study; however, the data should be considered in the interpretation of clinical trials in which adriamycin and verapamil are used together, both in terms of toxicity and tumour response.

Citing Articles

Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective.

Taskar K, Yang X, Neuhoff S, Patel M, Yoshida K, Paine M Clin Pharmacol Ther. 2022; 112(3):573-592.

PMID: 35612761 PMC: 9436425. DOI: 10.1002/cpt.2670.

Circumvention of P-gp and MRP2 mediated efflux of lopinavir by a histidine based dipeptide prodrug.

Mandal A, Pal D, Mitra A Int J Pharm. 2016; 512(1):49-60.

PMID: 27543355 PMC: 5030192. DOI: 10.1016/j.ijpharm.2016.08.027.

Mechanisms of doxorubicin resistance in hepatocellular carcinoma.

Cox J, Weinman S Hepat Oncol. 2016; 3(1):57-59.

PMID: 26998221 PMC: 4792121. DOI: 10.2217/hep.15.41.

P-glycoprotein Inhibition for Optimal Drug Delivery.

Amin M Drug Target Insights. 2013; 7:27-34.

PMID: 24023511 PMC: 3762612. DOI: 10.4137/DTI.S12519.

Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Dong X, Mumper R Nanomedicine (Lond). 2010; 5(4):597-615.

PMID: 20528455 PMC: 2925023. DOI: 10.2217/nnm.10.35.

References

Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y . Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res. 1983; 43(6):2905-10. View

Cole S, Flanagan R, Johnston A, Holt D . Rapid high-performance liquid chromatographic method for the measurement of verapamil and norverapamil in blood plasma or serum. J Chromatogr. 1981; 218:621-9. DOI: 10.1016/s0021-9673(00)82087-7. View

MEREDITH P, Elliott H, Pasanisi F, Kelman A, Sumner D, Reid J . Verapamil pharmacokinetics and apparent hepatic and renal blood flow. Br J Clin Pharmacol. 1985; 20(2):101-6. PMC: 1400678. DOI: 10.1111/j.1365-2125.1985.tb05038.x. View

Ballet F, Barbare J, Poupon R . Hepatic extraction of adriamycin in patients with hepatocellular carcinoma. Eur J Cancer Clin Oncol. 1984; 20(6):761-4. DOI: 10.1016/0277-5379(84)90213-x. View

Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y . Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 1982; 42(11):4730-3. View

Mullerleile U, Garbrecht M, Hanrath P, Langenstein B, Bieber K, BLEIFELD W . [Possible prevention of adriamycin-induced cardiomyopathy by verapamil. Results of a pilot study]. Klin Wochenschr. 1984; 62(21):1032-7. DOI: 10.1007/BF01711726. View

Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y . Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res. 1983; 43(5):2267-72. View

Macphee G, McInnes G, Thompson G, Brodie M . Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet. 1986; 1(8483):700-3. DOI: 10.1016/s0140-6736(86)91099-8. View

Burnakis T, Seldon M, Czaplicki A . Increased serum theophylline concentrations secondary to oral verapamil. Clin Pharm. 1983; 2(5):458-61. View

10.

Gurtoo H, Gessner T, Culliton P . Studies of the effects of cyclophosphamide, vincristine, and prednisone on some hepatic oxidations and conjugations. Cancer Treat Rep. 1976; 60(9):1285-94. View

11.

Yalowich J, Zucali J, Gross M, Ross W . Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro. Cancer Res. 1985; 45(10):4921-4. View

12.

Renton K . Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem Pharmacol. 1985; 34(14):2549-53. DOI: 10.1016/0006-2952(85)90541-6. View

13.

Cummings J, Stuart J, Calman K . Determination of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography. J Chromatogr. 1984; 311(1):125-33. DOI: 10.1016/s0378-4347(00)84698-8. View

14.

Riggs Jr C, Benjamin R, SERPICK A, Bachur N . Bilary disposition of adriamycin. Clin Pharmacol Ther. 1977; 22(2):234-41. DOI: 10.1002/cpt1977222234. View

15.

Kaelin Jr W, Shrivastav S, SHAND D, Jirtle R . Effect of verapamil on malignant tissue blood flow in SMT-2A tumor-bearing rats. Cancer Res. 1982; 42(10):3944-9. View

16.

Kaye S, Merry S . Tumour cell resistance to anthracyclines--a review. Cancer Chemother Pharmacol. 1985; 14(2):96-103. DOI: 10.1007/BF00434344. View